GLP-1 Peptide Atlas, by Delfa

CompletedPhase 1Results posted

A Study of Two Different Formulations of LY3502970 in Healthy Participants

A Phase 1 Multiple-Dose Study to Investigate the Pharmacokinetics, Safety, and Tolerability of 2 Different Formulations of LY3502970 in Healthy Participants

Lead sponsor

Eli Lilly and Company

Asset

Orforglipron

Oral · GLP-1 agonist

Listed sites

Recruiting sites

—

Enrollment

actual

Study population

Healthy volunteers

Key I/E criteria

•BMI 18.5-35•Healthy volunteers

Primary endpoints

•Cmax of LY3502970 in Formulation 1 and Formulation 2•PK: Area Under the Plasma Concentration-Time Curve (AUC) From 0 to 24 Hours•PK: Time to Maximum Observed Concentration (Tmax) of LY3502970 in Formulation 1

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT05341089

Org study ID17785

Secondary IDJ2A-MC-GZGHEli Lilly and Company

Timeline

Milestones

Study first posted2022-04-22actual

Study start2022-05-17actual

Primary completion2022-09-01actual

Study completion2022-09-01actual

Last update posted2026-05-27actual

Results first posted2026-05-27actual

Assets

Investigational agents

Orforglipron

Study populations

Who this study enrolls

Healthy volunteers

Eligibility

Who can enroll

Minimum age21 Years

Maximum age70 Years

SexAll

Healthy volunteersAccepted

Inclusion criteria

•Are overtly healthy as determined by medical evaluation

•Participants who have a hemoglobin level of at least 11.4 grams per deciliter (g/dL) for female participants and at least 12.5 g/dL for male participants

•Participants with a body weight of at least 45 kilograms (kg) and body mass index (BMI) of 18.5 to 35.0 kilograms per meter squared (kg/m²)

•Male participants who agree to use highly effective/effective methods of contraception and female participants not of childbearing potential

Exclusion criteria

•Participants who have any abnormality in the 12-lead electrocardiogram (ECG) at screening

•Participants who have an abnormal blood pressure, pulse rate, or both, which are deemed to be clinically significant by the investigator, at screening

•Participants who have known allergies to LY3502970, related compounds, or any components of the formulation

•Participants who have used or intend to use over-the-counter or prescription medication including herbal medications or traditional medications within 14 days prior to dosing

•Participants who show evidence of human immunodeficiency virus (HIV) infection and/or positive HIV antibodies, or both. A negative test within 6 months of screening would not need to be repeated.

•Participants who show evidence of hepatitis C and/or positive hepatitis C antibody, or both. A negative test within 6 months of screening would not need to be repeated.

•Participants who show evidence of hepatitis B, positive hepatitis B surface antigen, and/or positive hepatitis B core antibody, or all. A negative test within 6 months of screening would not need to be repeated.

Endpoints (6)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Safety / tolerability / PK

6 endpoints

Primary/registry result

Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY3502970 in Formulation 1 and Formulation 2

Time frame:Test Period 1 (Day 28) and Test Period 2 (Day 35): Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hours postdose

concentration, descriptive

Posted result

Group	Value (geometric_mean), nanogram per milliliter (ng/mL)	95% CI
16 mg LY3502970 (Formulation 1)	86.5	—
16 mg LY3502970 (Formulation 2)	86.5	—

Primary/registry result

PK: Area Under the Plasma Concentration-Time Curve (AUC) From 0 to 24 Hours (AUC (0-24)) of LY3502970 in Formulation 1 and Formulation 2

Time frame:Test Period 1 (Day 28) and Test Period 2 (Day 35): Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hours postdose

concentration, descriptive

Posted result

Group	Value (geometric_mean), Nanogramhour per milliliter (ngh/mL)	95% CI
16 mg LY3502970 (Formulation 1)	1260	—
16 mg LY3502970 (Formulation 2)	1240	—

Primary/registry result

PK: Time to Maximum Observed Concentration (Tmax) of LY3502970 in Formulation 1 and Formulation 2

Time frame:Test Period 1 (Day 28) and Test Period 2 (Day 35): Predose, 0.5, 1, 2, 4, 6, 8, 12, 16, 24 hours postdose

time to event, event

Posted result

Group	Value (median), Hours (h)	95% CI
16 mg LY3502970 (Formulation 1)	6.00	4.00 – 23.92
16 mg LY3502970 (Formulation 2)	6.00	2.00 – 12.00

Primary/protocol endpoint

Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of LY3502970

Time frame:Pre-dose on Day 1 up to 39 days post-dose

Cmax

concentration, descriptive

Primary/protocol endpoint/low confidence

PK: Area Under the Plasma Concentration-Time Curve from 0 to 24 hours (AUC0-24) of LY3502970

Time frame:Pre-dose on Day 1 up to 39 days post-dose

concentration, descriptive

Primary/protocol endpoint

PK: Time to Maximum Observed Concentration (Tmax) of LY3502970

Time frame:Pre-dose on Day 1 up to 39 days post-dose

Tmax

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableClinicalTrials.gov results section

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.